256 related articles for article (PubMed ID: 22247763)
1. Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.
Keravis T; Monneaux F; Yougbaré I; Gazi L; Bourguignon JJ; Muller S; Lugnier C
PLoS One; 2012; 7(1):e28899. PubMed ID: 22247763
[TBL] [Abstract][Full Text] [Related]
2. NCS 613, a PDE4 inhibitor, by increasing cAMP level suppresses systemic inflammation and immune complexes deposition in kidney of MRL/lpr lupus- prone mice.
Yougbare I; Keravis T; Lugnier C
Biochim Biophys Acta Mol Basis Dis; 2021 Mar; 1867(3):166019. PubMed ID: 33227426
[TBL] [Abstract][Full Text] [Related]
3. NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.
Yougbare I; Morin C; Senouvo FY; Sirois C; Albadine R; Lugnier C; Rousseau E
Am J Physiol Lung Cell Mol Physiol; 2011 Oct; 301(4):L441-50. PubMed ID: 21784969
[TBL] [Abstract][Full Text] [Related]
4. NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production.
Yougbaré I; Boire G; Roy M; Lugnier C; Rouseau E
Can J Physiol Pharmacol; 2013 May; 91(5):353-61. PubMed ID: 23656347
[TBL] [Abstract][Full Text] [Related]
5. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
[TBL] [Abstract][Full Text] [Related]
6. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.
MacKenzie SJ; Houslay MD
Biochem J; 2000 Apr; 347(Pt 2):571-8. PubMed ID: 10749688
[TBL] [Abstract][Full Text] [Related]
7. Cyclic GMP catabolism up-regulation in MRL/lpr lupus-prone mice is associated with organ remodeling.
Yougbaré I; Keravis T; Abusnina A; Decossas M; Schall N; Muller S; Lugnier C
Biochim Biophys Acta; 2014 Jul; 1842(7):916-26. PubMed ID: 24631654
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of phosphodiesterase-4 in the spinal dorsal horn ameliorates neuropathic pain via cAMP-cytokine-Cx43 signaling in mice.
Zhang FF; Wang H; Zhou YM; Yu HY; Zhang M; Du X; Wang D; Zhang F; Xu Y; Zhang JG; Zhang HT
CNS Neurosci Ther; 2022 May; 28(5):749-760. PubMed ID: 35156776
[TBL] [Abstract][Full Text] [Related]
9. Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway.
Chen XC; Wu D; Wu HL; Li HY; Yang C; Su HY; Liu ZJ; Huang XR; Lu X; Huang LF; Zhu SP; Pan QJ; An N; Liu HF
Lupus Sci Med; 2022 Apr; 9(1):. PubMed ID: 35414608
[TBL] [Abstract][Full Text] [Related]
10. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.
Saldou N; Obernolte R; Huber A; Baecker PA; Wilhelm R; Alvarez R; Li B; Xia L; Callan O; Su C; Jarnagin K; Shelton ER
Cell Signal; 1998 Jun; 10(6):427-40. PubMed ID: 9720765
[TBL] [Abstract][Full Text] [Related]
11. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages.
Jin SL; Lan L; Zoudilova M; Conti M
J Immunol; 2005 Aug; 175(3):1523-31. PubMed ID: 16034090
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
14. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
15. Regulation of 3',5'-cAMP in preglomerular smooth muscle and endothelial cells from genetically hypertensive rats.
Cheng D; Ren J; Gillespie DG; Mi Z; Jackson EK
Hypertension; 2010 Dec; 56(6):1096-101. PubMed ID: 20975032
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4B negatively regulates endotoxin-activated interleukin-1 receptor antagonist responses in macrophages.
Yang JX; Hsieh KC; Chen YL; Lee CK; Conti M; Chuang TH; Wu CP; Jin SC
Sci Rep; 2017 Apr; 7():46165. PubMed ID: 28383060
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice.
Hecht M; Müller M; Lohmann-Matthes ML; Emmendörffer A
J Leukoc Biol; 1995 Feb; 57(2):242-9. PubMed ID: 7852838
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
20. PDTC attenuate LPS-induced kidney injury in systemic lupus erythematosus-prone MRL/lpr mice.
Zhai JX; Zhang ZX; Feng YJ; Ding SS; Wang XH; Zou LW; Ye DQ
Mol Biol Rep; 2012 Jun; 39(6):6763-71. PubMed ID: 22318546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
